Viroloxía e Patoxénese ‘VIP’

Investigadores Responsable(s)

Eva Poveda López

BSc Biol, PhD Microbioloxía Médica
eva.poveda.lopez@sergas.es

986 217 463

Investigadores Posdoutorais

Ana Borrajo López

BSc Biol, PhD Bioloxía
ana.borrajo.lopez@sergas.es

986 217 463

Investigadores Predoutorais

Andrés Tabernilla García

BSc Biol Bioloxía
andres.tabernilla.garcia@sergas.es

986 217 463

Marta Grandal Fustes

BSc Biol Bioloxía
marta.grandal.fustes@sergas.es

986 217 463

Persoal técnico de apoio

Lucía Cristina Patino Álvarez

BSc, Tech Bioloxía Molecular e Epixenética

Colaboradores Externos

Ana Isabel Marino Callejo

MD Enfermidades Infecciosas

EOXI-Ferrol

Antonio Aguilera Guirao

PharmD Microbioloxía

EOXI-SANTIAGO

Dimitrios Paraskevis

BSc Phys Epidemioloxía Molecular

National and Kapodistrian University of Athens

Federico García García

PharmD Microbioloxía

Ibs.GRANADA

George Yendewa

MD, MPH & TM, DrPH (cand) Enfermidades Infecciosas

Case Western Reserve University School of Medicine (OH, US)

Hortensia Álvarez Díaz

MD Enfermidades Infecciosas

EOXI-FERROL

Michael Freeman

BSc Biol, PhD Viroloxía Molecular e Microbioloxía

Case Western Reserve University (OH, US)

Michael Lederman

MD Microbioloxía, Bioloxía Molecular e Ética Biomédica

Case Western Reserve University (OH, US)

Nieves Valcarce Pardeiro

BPharm Enfermidades Infecciosas

EOXI-FERROL

Virus da Inmunodeficiencia Humana (VIH)
Patoxénese
Epidemioloxía molecular
Activación / Inflamación
Resistencia a fármacos

– Epidemioloxía Molecular da infección por VIH incluindo estudos de prevalencia e caracterización de resistencias a fármacos.
– Impacto d0 tratamento antirretroviral (ART) na viremia residual e nos niveis de activación/inflamación na infección por VIH.
– Estudo do papel do ADNmt nas infeccións virais: impacto na evolución e patoxénese da infección.
– Estudo do papel das vesículas extracelulares e a mitocondria nas infeccións virais: impacto na patoxénesis da infección.
– Estudos de Resistencias a fármacos e co-infeccions virais na África Occidental.

2014

2015

2016

2017

Artigos Científicos

AIDS Study Group (GeSIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology and the National AIDS Plan:. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018). Enferm Infecc Microbiol Clin. 2019 Mar;37(3):195-202. doi: 10.1016/j.eimc.2018.02.010. Epub 2018 Jun 18. English, Spanish. PubMed PMID: 29759422. +Pubmed
Alvarez M, Casas P, de Salazar A, Chueca N, Guerrero-Beltran C, Rodríguez C, Imaz A, Espinosa N, García-Bujalance S, Pérez-Elías MJ, García-Alvarez M, Iribarren JA, Santos J, Dalmau D, Aguilera A, Vinuesa D, Gutiérrez F, Piérola B, Molina JM, Peraire J, Portilla I, Gómez-Sirvent JL, Olalla J, Galera C, Blanco JR, Riera M, García-Fraile L, Navarro G, Curran A, Poveda E, García F; CoRIS . Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice. J Antimicrob Chemother. 2019 Jun 1;74(6):1693-1700. doi: 10.1093/jac/dkz067. PubMed PMID: 30838386. +Pubmed
Cid-Silva P, Fernández-Bargiela N, Margusino-Framinán L, Balboa-Barreiro V, Mena-De-Cea Á, López-Calvo S, Vázquez-Rodríguez P, Martín-Herranz I, Míguez-Rey E, Poveda E, Castro-Iglesias Á. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine. Basic Clin Pharmacol Toxicol. 2019 Apr;124(4):479-490. doi: 10.1111/bcpt.13161. Epub 2018 Dec 7. PubMed PMID: 30388308. +Pubmed
Cid-Silva P, Margusino-Framinán L, Balboa-Barreiro V, Pernas-Souto B, Mena-De-Cea Á, Martín-Herranz I, Castro-Iglesias Á, Poveda E. Late HIV Diagnosis but Earlier Antiretroviral Treatment Initiation in Northwest Spain: Impact of Current Treatment Guidelines. J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958218821940. doi: 10.1177/2325958218821940. PubMed PMID: 30798655. +Pubmed
De Mendoza C, Pirón M, Gonzalez R, Jiménez A, Caballero E, Roc L, Benito R, Ramos JM, Soriano V; HTLV Spanish Study Group . Clinical Presentation of Individuals With Human T-Cell Leukemia Virus Type-1 Infection in Spain. Open Forum Infect Dis. 2019 Jan 16;6(2):ofz036. doi: 10.1093/ofid/ofz036. eCollection 2019 Feb. PubMed PMID: 30815504; PubMed Central PMCID: PMC6386801. +Pubmed
Yendewa GA, Sahr F, Aguilera A, Lakoh S, Sesay M, Deen GF, Patino L, Poveda E, Salata RA. Seroprevalence of Hepatitis B, Hepatitis C, and Human T-Cell Lymphotropic Virus Infections in HIV-Infected Patients in Sierra Leone. Am J Trop Med Hyg. 2019 Jun;100(6):1521-1524. doi: 10.4269/ajtmh.18-1001. PubMed PMID: 30938283. +Pubmed
Yendewa GA, Sahr F, Lakoh S, Ruiz M, Patino L, Tabernilla A, Deen GF, Sesay M, Salata RA, Poveda E. Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone. J Antimicrob Chemother. 2019 Apr 15. pii: dkz134. doi: 10.1093/jac/dkz134. [Epub ahead of print] PubMed PMID: 30989237. +Pubmed

Artigos Científicos

AIDS Study Group (GESIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology and the National AIDS Plan. Executive summary of the GESIDA/National AIDS Plan Consensus Document on Antiretroviral Therapy in Adults Infected by the Human Immunodeficiency Virus (Updated January 2017). Enferm Infecc Microbiol Clin. 2018 Aug – Sep;36(7):435-445. doi: 10.1016/j.eimc.2017.04.001. Epub 2017 Jun 1. English, Spanish. PubMed PMID: 28579016. +Pubmed
AIDS Study Group (GeSIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Executive summary of the GeSIDA consensus document on control and monitoring of HIV-infected patients. Enferm Infecc Microbiol Clin. 2018 May;(E-PUB) PMID: 29793873. http://www.ncbi.nlm.nih.gov/pubmed/29793873 +Pubmed +DOI
Cid-Silva P, Margusino-Framinán L, Balboa-Barreiro V, Martín-Herranz I, Castro-Iglesias Á, Pernas-Souto B, Llibre JM, Poveda E. Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors. AIDS. 2018 Jan;32(1):121-5. PMID: 29112068. IF2016: 5.019; Q1. http://www.ncbi.nlm.nih.gov/pubmed/29112068 +Pubmed +DOI
Grandal M, Pernas B, Tabernilla A, Marino A, Álvarez H, Valcarce N, Mena A, Castro-Iglesias A, Pérez AB, Delgado M, Poveda E. Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies. J Med Virol. 2018 Jun;90(6):1094-8. PMID: 29427437. http://www.ncbi.nlm.nih.gov/pubmed/29427437 +Pubmed +DOI
Lemey P, Stanojevic M, Vandamme A-M. Optimization of the results generated by large-scale sequenc- ing for the study of drug resistance in HIV infection: A system- atic review. International BioInformatics Workshop on Virus Evolution and Molecular Epidemiology. Infect Genet Evol. 2018 Apr;19:335-6. DOI: 10.1016/j.meegid.2013.08.023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905554/pdf/vey010.001.pdf +Pubmed +DOI
Poveda E, Crespo M. Hot News: Impact of Low-level Viremia on Treatment Outcomes During ART – Is it Time to Revise the Definition of Virological Failure? AIDS Rev. 2018;20(1):71-2. PMID: 29628513. http://www.ncbi.nlm.nih.gov/pubmed/29628513 +Pubmed
Yendewa GA, Poveda E, Lakoh S, Yendewa SA, Jiba DF, Salgado-Barreira A, Sahr F, Salata RA. High Prevalence of Late-Stage Disease in Newly Diagnosed Human Immunodeficiency Virus Patients in Sierra Leone. Open Forum Infect Dis. 2018 Aug 23;5(9):ofy208. doi: 10.1093/ofid/ofy208. eCollection 2018 Sep. PubMed PMID: 30191158; PubMed Central PMCID: PMC6121223. +Pubmed
Yendewa GA, Poveda E, Yendewa SA, Sahr F, Quinones-Mateu ME, Salata RA. HIV/AIDS in Sierra Leone: Characterizing the Hidden Epidemic. AIDS Rev. 2018 Apr-Jun;20(2):104-113. Review. PubMed PMID: 29938704. +Pubmed

Artigos Científicos

Cid-Silva P, Llibre JM, Fernández-Bargiela N, Margusino-Framinán L, Balboa-Barreiro V, Pernas-Souto B, Martín-Herranz I, Castro-Iglesias Á, Poveda E. Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance. Basic Clin Pharmacol Toxicol. 2017 Nov;121(5):442-6. PMID: 28627771. IF2017:2.659; Q2. http://www.ncbi.nlm.nih.gov/pubmed/28627771 +Pubmed +DOI
de Mendoza C, Caballero E, Aguilera A, Requena S, de Lejarazu RO, Pirón M, González R, Jiménez A, Roc L, Trevino A, Benito R, Fernández-Alonso M, Aguinaga A, Rodríguez C, García-Costa J, Blanco L, Ramos JM, Calderón E, Eirós JM, Sauleda S, Barreiro P, Soriano V, Spanish HTLV Network (Morano L; Pérez-Castro S; Poveda E). Human T-lymphotropic virus type 1 infection and disease in Spain. AIDS. 2017 Jul;31(12):1653-63. PMID: 28700391. IF2017: 4.914; Q1. http://www.ncbi.nlm.nih.gov/pubmed/28700391 +Pubmed +DOI
Fernández-Caballero JA, Chueca N, Poveda E, García F. Minimizing Next-Generation Sequencing Errors for HIV Drug Resistance Testing. AIDS Rev. 2017;19(4):231-8. PMID: 28534892. IF2017: 2.775; Q2. http://www.ncbi.nlm.nih.gov/pubmed/28534892 +Pubmed
Grandal M, Pernas B, Marino A, Álvarez H, Tabernilla A, Castro-Iglesias Á, Mena Á, Delgado M, Pértega S, Poveda E. Characterization of chronic HCV infection in Northwest Spain: Impact of the treatment strategic plan of the Spanish National Health Service on HCV cure. J Med Virol. 2017 Jul;89(7):1304-8. PMID: 28079256. IF2017: 1.988; Q3. http://www.ncbi.nlm.nih.gov/pubmed/28079256 +Pubmed +DOI
Meijide H, Mena Á, Rodríguez-Osorio I, Castro-Iglesias Á, Poveda E. Cancer Incidence in Persons Living With HIV. Clin Infect Dis. 2017 Feb;64(3):388-9. PMID: 28013260. IF2017: 9.117; D1. http://www.ncbi.nlm.nih.gov/pubmed/28013260 +Pubmed +DOI
Meijide H, Mena Á, Rodríguez-Osorio I, Pértega S, Castro-Iglesias Á, Rodríguez-Martínez G, Pedreira J, Poveda E. Trends in hospital admissions, re-admissions, and in-hospital mortality among HIV-infected patients between 1993 and 2013: Impact of hepatitis C co-infection. Enferm Infecc Microbiol Clin. 2017 Jan;35(1):20-6. PMID: 27609631. IF2017: 1.707; Q3. http://www.ncbi.nlm.nih.gov/pubmed/27609631 +Pubmed +DOI
Meijide H, Pértega S, Rodríguez-Osorio I, Castro-Iglesias Á, Balinas J, Rodríguez-Martínez G, Mena Á, Poveda E. Increased incidence of cancer observed in HIV/hepatitis C virus-coinfected patients versus HIV-monoinfected. AIDS. 2017 May;31(8):1099-107. PMID: 28441174. IF2017: 4.914; Q1. http://www.ncbi.nlm.nih.gov/pubmed/28441174 +Pubmed +DOI
Mena A, Meijide H, Rodríguez-Osorio I, Castro A, Poveda E. Liver-related mortality and hospitalizations attributable to chronic hepatitis C virus coinfection in persons living with HIV. HIV Med. 2017 Oct;18(9):685-9. PMID: 28230318. IF2017: 2.932; Q2. http://www.ncbi.nlm.nih.gov/pubmed/28230318 +Pubmed +DOI
Pernas B, Rego-Pérez I, Tabernilla A, Balboa V, Relano S, Grandal M, Crespo M, Mena Á, Castro-Iglesias Á, Blanco FJ, Poveda E. Plasma mitochondrial DNA levels are inversely associated with HIV-RNA levels and directly with CD4 counts: potential role as a biomarker of HIV replication. J Antimicrob Chemother. 2017 Nov;72(11):3159-62. PMID: 28961892. IF2017: 5.217; D1. http://www.ncbi.nlm.nih.gov/pubmed/28961892 +Pubmed +DOI
Poveda E, Crespo M. When is Early Antiretroviral Therapy Early Enough for HIV Remission? AIDS Rev. 2017 Apr;19(2):113-4. PMID: 28534887. IF2017: 2.775; Q2. http://www.ncbi.nlm.nih.gov/pubmed/28534887 +Pubmed
Poveda E, Freeman ML. Hot News: Exosomes as New Players in HIV Pathogenesis – New Data from the IAS 2017. AIDS Rev. 2017;19(3):173-5. PMID: 29019351. IF2017: 2.775; Q2. http://www.ncbi.nlm.nih.gov/pubmed/29019351 +Pubmed
Poveda E, Hernández-Quero J, Pérez-Elías MJ, Ribas MA, Martínez-Madrid OJ, Flores J, Navarro J, Gutiérrez F, García-Deltoro M, Imaz A, Ocampo A, Artero A, Blanco F, Bernal E, Pasquau J, Mínguez-Gallego C, Pérez N, Aiestaran A, García F, Paredes R, PROTEST study group. Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study. HIV Med. 2017 Aug;18(7):482-9. PMID: 28035758. IF2017: 2.932; Q2. http://www.ncbi.nlm.nih.gov/pubmed/28035758 +Pubmed +DOI
Poveda E, Martin-Gayo E. Similar Immunological Profiles Between Nonprogressing HIV Infection in Children and Nonpathogenic SIV Infection. AIDS Rev. 2017;19(1):54-5. PMID: 28182614. IF2017: 2.775; Q2. http://www.ncbi.nlm.nih.gov/pubmed/28182614 +Pubmed
Poveda E, Puoti M, García-Deltoro M, Pineda JA, Téllez F, Granados R, Morano L, García F, Grupo de Estudio de Hepatitis Víricas (GEHEP). News on Viral Hepatitis in HIV: Update from the 2016 GEHEP Conference. AIDS Rev. 2017 Jan;19(1):47-53. PMID: 28182613. IF2017: 2.775; Q2. http://www.ncbi.nlm.nih.gov/pubmed/28182613 +Pubmed
Rodríguez-Osorio I, Cid P, Morano L, Castro Á, Suárez M, Delgado M, Margusino L, Meijide H, Pernas B, Tabernilla A, Pedreira JD, Mena Á, Poveda E. Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients. J Clin Virol. 2017 Mar;88:58-61. PMID: 28183063. IF2017: 3.101; Q2. http://www.ncbi.nlm.nih.gov/pubmed/28183063 +Pubmed +DOI
Tabernilla A, Grandal M, Pernas B, Castro-Iglesias A, Rodríguez-Osorio I, Mena A, Delgado M, Cid P, Pedreira JD, Poveda E. Short article: Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration. Eur J Gastroenterol Hepatol. 2017 Jul;29(7):781-5. PMID: 28410351. IF2017: 2.014; Q4. http://www.ncbi.nlm.nih.gov/pubmed/28410351 +Pubmed +DOI
Trevino A, Aguilera A, Rodríguez-Iglesias MA, Hernandez A, Benito R, Roc L, Ramos JM, Ortíz de Lejarazu R, Poveda E, Rodríguez C, Del Romero J, Calderon E, García J, Requena S, Soriano V, de Mendoza C. HTLV infection in HCV-antibody positive patients in Spain. AIDS Res Hum Retroviruses. 2017 Mar;33(10):1013-7. PMID: 28269998. IF2017: 1.935; Q3. http://www.ncbi.nlm.nih.gov/pubmed/28269998 +Pubmed +DOI

Artigos Científicos

Pernas B, Grandal M, Pertega S, Canizares A, Castro-Iglesias Á, Mena Á, Rodriguez-Osorio I, Tabernilla A, Pedreira JD, Poveda E. Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART? J Antimicrob Chemother. 2016 Apr;71(4):1051-5. PMID: 26702924. http://www.ncbi.nlm.nih.gov/pubmed/26702924 +Pubmed +DOI
Pernas B, Grandal M, Tabernilla A, Cid P, Pértega S, Castro-Iglesias Á, Mena Á, Margusino L, Pedreira JD, Poveda E. Long-term clinical experience with darunavir (2007-2015) in a large cohort of HIV-infected patients in Spain. J Med Virol. 2016;88(12):2125-31. PMID: 27218208. http://www.ncbi.nlm.nih.gov/pubmed/27218208 +Pubmed +DOI
Poveda E, Crespo M. New Strategies for a Comprehensive Fight Against HIV Infection using Monoclonal Antibody Therapy. AIDS Rev. 2016 Jul;18(3):166. PMID: 27721508. IF2016: 3.195; Q2. http://www.ncbi.nlm.nih.gov/pubmed/27721508 +Pubmed
Poveda E, Tabernilla A. New Insights into HIV-1 Persistence in Sanctuary Sites During Antiretroviral Therapy. AIDS Rev. 2016;18(1):55. PMID: 27028272. http://www.ncbi.nlm.nih.gov/pubmed/27028272 +Pubmed
Tabernilla A, Rego-Pérez I, Grandal M, Pernas B, Pértega S, Delgado M, Marino A, Álvarez H, Mena A, Rodríguez-Osorio I, Pedreira JD, Blanco FJ, Poveda E. Brief Report: European Mitochondrial Haplogroups Impact on Liver Fibrosis Progression Among HCV and HIV/HCV-Coinfected Patients From Northwest Spain. J Acquir Immune Defic Syndr. 2016;73(2):149-53. PMID: 27258234. http://www.ncbi.nlm.nih.gov/pubmed/27258234 +Pubmed +DOI

Artigos Científicos

Meijide H, Mena A, Marcos PJ, Rodriguez-Osorio I, Suárez-Fuentetaja R, Castro A, Poveda E, Pedreira JD. Lung cancer in patients living with HIV infection. AIDS. 2015 Nov;29(17):2363-4. PMID: 26544707. IF2015: 4.407; Q1. http://www.ncbi.nlm.nih.gov/pubmed/26544707 +Pubmed +DOI
Paraskevis D, Kostaki E, Beloukas A, Canizares A, Aguilera A, Rodríguez J, Grandal M, Pernas B, Castro-Iglesias A, Mena Á, Pedreira JD, Poveda E. Molecular characterization of HIV-1 infection in Northwest Spain (2009-2013): Investigation of the subtype F outbreak. Infect Genet Evol. 2015 Mar;30:96-101. PMID: 25527396. http://www.ncbi.nlm.nih.gov/pubmed/25527396 +Pubmed +DOI
Pernas B, Mena A, Canizares A, Grandal M, Castro-Iglesias A, Pértega S, Pedreira JD, Poveda E. Trends on epidemiological, virological, and clinical features among newly diagnosed HIV-1 persons in Northwest Spain over the last 10 years. J Med Virol. 2015 Aug;87(8):1319-26. PMID: 25777786. http://www.ncbi.nlm.nih.gov/pubmed/25777786 +Pubmed +DOI
Poveda E, Wyles D, Morano L, Pineda JA, García F, Grupo de Estudio de Hepatitis Víricas (GEHEP), E P, D W, L M, JA P, F G, GEHEP. News on HIV-HCV coinfection: Update from the 2015 GEHEP conference. AIDS Rev. 2015 Oct;17(4):231-7. PMID: 26616846. IF2015: 2.068; Q3. http://www.ncbi.nlm.nih.gov/pubmed/26616846 +Pubmed
Poveda E. Discovery of a Natural Defense Against HIV With Therapeutic Potential. AIDS Rev. 2015;17(4):238. PMID: 26690492. IF2015: 2.068; Q3. http://www.ncbi.nlm.nih.gov/pubmed/26690492 +Pubmed
Poveda E. HIV tropism shift: new paradigm on cell therapy strategies for HIV cure. AIDS Rev. 2015;17(1):65. PMID: 25608470. IF2015: 2.068; Q3. http://www.ncbi.nlm.nih.gov/pubmed/25608470 +Pubmed
Tabernilla A, Poveda E. The START Trial: Definitive Evidence to Treat All HIV-Positive Persons Regardless of CD4 Counts. AIDS Rev. 2015;17(3):187. PMID: 26450809. IF2015: 2.068; Q3. http://www.ncbi.nlm.nih.gov/pubmed/26450809 +Pubmed
Trevino A, Caballero E, de Mendoza C, Aguilera A, Pirón M, Soriano V, Spanish HIV-2/HTLV Study Group. The Burden of Neglected HIV-2 and HTLV-1 Infections in Spain. AIDS Rev. 2015;17(4):212-9. PMID: 26616845. IF2015: 2.068; Q3. http://www.ncbi.nlm.nih.gov/pubmed/26616845 +Pubmed

Artigos Científicos

de Mendoza C, Caballero E, Aguilera A, Pirón M, Ortiz de Lejarazu R, Rodríguez C, Cabezas T, González R, Trevino A, Soriano V, Spanish HIV-2/HTLV Group. HIV-2 and HTLV-1 infections in Spain, a non-endemic region. AIDS Rev. 2014;16(3):152-9. PMID: 25180694. IF2014: 2.775; Q2. http://www.ncbi.nlm.nih.gov/pubmed/25180694 +Pubmed
Garcia F, Poveda E, Pérez-Elías MJ, Quero JH, Ribas MA, Martínez-Madrid OJ, Flores J, Crespo M, Gutiérrez F, García-Deltoro M, Imaz A, Ocampo A, Artero A, Blanco F, Bernal E, Pasquau J, Mínguez-Gallego C, Pérez N, Aiestarán A, Paredes R. Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study. J Int AIDS Soc. 2014 Jan;17(4 Suppl 3):19520. PMID: 25394029. IF: 5.090; Q1. http://www.ncbi.nlm.nih.gov/pubmed/25394029 +Pubmed +DOI
Mena A, Moldes L, Meijide H, Canizares A, Castro-Iglesias A, Delgado M, Pértega S, Pedreira J, Bou G, Poveda E. Seroprevalence of HCV and HIV infections by year of birth in Spain: impact of US CDC and USPSTF recommendations for HCV and HIV testing. PLoS One. 2014;9(12):e113062. PMID: 25436642. IF2014: 3.234; Q1. http://www.ncbi.nlm.nih.gov/pubmed/25436642 +Pubmed +DOI
Mena Á, Pedreira JD, Castro Á, López S, Vázquez P, Poveda E. Metabolic syndrome association with fibrosis development in chronic hepatitis B virus inactive carriers. J Gastroenterol Hepatol. 2014 Jan;29(1):173-8. PMID: 24219115. IF2014: 3.504; Q2. http://www.ncbi.nlm.nih.gov/pubmed/24219115 +Pubmed +DOI
Monge S, Guillot V, Alvarez M, Chueca N, Stella N, Pena A, Delgado R, Córdoba J, Aguilera A, Vidal C, García F, CoRIS. Clinically relevant transmitted drug resistance to first line antiretroviral drugs and implications for recommendations. PLoS One. 2014;9(3):e90710. PMID: 24637804. IF2014: 3.234; Q1. http://www.ncbi.nlm.nih.gov/pubmed/24637804 +Pubmed +DOI
Pernas B, Grandal M, Mena A, Castro-Iglesias A, Canizares A, Wyles DL, López-Calvo S, Pértega S, Rodríguez-Osorio I, Pedreira JD, Poveda E. High prevalence of subtype F in newly diagnosed HIV-1 persons in northwest Spain and evidence for impaired treatment response. AIDS. 2014 Jul;28(12):1837-40. PMID: 24871456. IF2014: 2.775; Q2. http://www.ncbi.nlm.nih.gov/pubmed/24871456 +Pubmed +DOI
Poveda E, Pedreira JD. Highlights from CROI 2014 on experimental HIV drugs. AIDS Rev. 2014;16(2):118. PMID: 24984767. IF2014: 2.775; Q2. http://www.ncbi.nlm.nih.gov/pubmed/24984767 +Pubmed
Poveda E, Wyles DL, Mena A, Pedreira JD, Castro-Iglesias A, Cachay E. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res. 2014 Aug;108(1):181-91. PMID: 24911972. http://www.ncbi.nlm.nih.gov/pubmed/24911972 +Pubmed +DOI
Poveda E. Ingenol derivates promising for HIV eradication. AIDS Rev. 2014;16(4):246. PMID: 25373349. IF2014: 2.775; Q2. http://www.ncbi.nlm.nih.gov/pubmed/25373349 +Pubmed
Poveda E. Multi-step inhibition against HIV lifecycle-underlying the “magic” of protease inhibitors. AIDS Rev. 2014;16(1):52. PMID: 24589971. IF2014: 2.775; Q2. http://www.ncbi.nlm.nih.gov/pubmed/24589971 +Pubmed
Trevino A, Soriano V, Poveda E, Parra P, Cabezas T, Caballero E, Roc L, Rodríguez C, Eiros JM, Lopez M, De Mendoza C, HIV-2 Spanish Study Group. HIV-2 viral tropism influences CD4+ T cell count regardless of viral load. J Antimicrob Chemother. 2014 Aug;69(8):2191-4. PMID: 24788659. IF: 5.313; Q1. http://www.ncbi.nlm.nih.gov/pubmed/24788659 +Pubmed +DOI

Código

BA18/00034

Título

Financiador

Instituto de Salud Carlos III

Tipo

Individual

Duración

2019 – 2019

Eva Poveda López

Código

RD16/0025/0026

Título

Red de SIDA de Espana

Financiador

Instituto de Salud Carlos III

Tipo

Multicéntrico

Duración

2018 – 2021

Eva Poveda López

Coordinador

José Alcamí Pertejo (Coord. )

Código

EQC2018-004581-P

Título

Fortalecimiento e integración de las plataformas de genómica y biología celular mediante técnicas avanzadas de fraccionamiento celular para el análisis de ácidos nucleicos por Digital PCR

Financiador

Ministerio de Ciencia, Innovación y Universidades

Tipo

Individual

Duración

2018 – 2019

Eva Poveda López

Cols.

A. Borrajo. A. Marino. A. Tabernilla. G. Yendewa. L. Patino. M. Grandal

Código

PI16/02159

Título

Impacto de las combinaciones terapéuticas actuales frente a la infección por VIH en la viremia residual y marcadores de inflamación/activación: implicaciones en el manejo clínico.

Financiador

Instituto de Salud Carlos III

Tipo

Multicéntrico

Duración

2017 – 2019

Eva Poveda López

Cols.

A. Tabernilla. M. Grandal

Código

IN606A-2016/023

Título

Contrato pre-doctoral – GAIN

Financiador

Axencia Galega de Innovación – GAIN

Tipo

Individual

Duración

2017 – 2019

Eva Poveda López

Cols.

A. Tabernilla

Código

IN606B-2016/012

Título

Contrato post-doctoral GAIN

Financiador

Axencia Galega de Innovación – GAIN

Tipo

Individual

Duración

2017 – 2019

Eva Poveda López

Cols.

A. Borrajo

Código

MV16/00054

Título

Contrato Movilidad Personal Investigador M-AES

Financiador

Instituto de Salud Carlos III

Tipo

Individual

Duración

2017 – 2017

Eva Poveda López

Código

FI14/00557

Título

Contratos predoctorales de formación en Investigación en Salud (PFIS)

Financiador

Instituto de Salud Carlos III

Tipo

Individual

Duración

2015 – 2019

Eva Poveda López

Cols.

M. Grandal

Código

PI13/02266

Título

Plataforma molecular para la caracterización virológica y genética de los pacientes con infección crónica por el virus de la hepatitis C: optimización de la terapia y curación

Financiador

Instituto de Salud Carlos III

Tipo

Multicéntrico

Duración

2014 – 2018

Eva Poveda López

Cols.

M. Grandal

Título

Inhibidores de la integrasa: eficacia y seguridad en el tratamiento de pacientes con infección por VIH

URL

https://www.educacion.gob.es/teseo/mostrarRef.do?ref=1782045

Doutorando

Purificación Cid Silva

Director

Eva Poveda López

Director(es)/Codirector(es) externo(s)

Ma Ángeles Castro-Iglesias

Universidade

Universidad de A Coruna

Data

07/06/2019

Título

Infección por el Virus de la Hepatitis C en la era de los antivirales de acción directa: optimización del diagnóstico, tratamiento y progresión de la enfermedad

URL

https://www.educacion.gob.es/teseo/mostrarRef.do?ref=1782324

Doutorando

Andrés Tabernilla García

Director

Eva Poveda López

Director(es)/Codirector(es) externo(s)

Ma Ángeles Castro Iglesias

Universidade

Universidad de A Coruna

Data

06/06/2019

Título

Impacto del virus de la hepatitis C en la evolución de las comorbilidades en pacientes infectados por el VIH (1993-2014).

URL

https://www.educacion.gob.es/teseo/mostrarRef.do?ref=1556259

Doutorando

Héctor Meijide Míguez

Director

Eva Poveda López

Universidade

Universidad de A Coruna

Data

23/11/2017

Título

Caracterización epidemiológica, clínica y virológica de los nuevos diagnósticos de infección por el VIH-1 (2004-2015): impacto en la respuesta al tratamiento antiretroviral

URL

https://www.educacion.gob.es/teseo/mostrarRef.do?ref=1317051

Doutorando

Berta Pernas Souto

Director

Eva Poveda López

Universidade

Universidad de A Coruna

Data

04/10/2016

Título

Resistencia a los nuevos antivirales frente al virus de la hepatitis C

URL

http://eprints.ucm.es/25208/

Doutorando

Zulema Plaza Almuedo

Director

Eva Poveda López

Universidade

Universidad Complutense de Madrid

Data

17/01/2014